This New Blood Test Could Spot Leukemia Risk Without The Painful Bone Marrow Sampling

Just days after their laboratories were devastated by an Iranian missile attack, Profs. Liran Shlush and Amos Tanay of the Weizmann Institute of Science have published a landmark study that could transform how we detect and predict leukemia and other blood disorders. Their research, released in Nature Medicine, introduces a revolutionary blood test that may one day replace the painful, invasive bone marrow biopsy—a procedure dreaded by patients and clinicians alike.Developed by Professors Liran Shlush and Amos Tanay, this innovation replaces the traditionally painful and invasive bone marrow biopsy with a cutting-edge, non-invasive blood test.This development is poised to revolutionize diagnostics in hematology and could dramatically reduce global dependence on bone marrow sampling — a procedure that over a million people endure each year globally.Why Bone Marrow Biopsies Have Been the Gold Standard?For decades, diagnosing blood cancers such as leukemia has relied on extracting bone marrow—a process that involves drilling into the bone, typically under local anesthesia or sedation. The procedure is not only uncomfortable and anxiety-inducing but also costly, technically demanding, and sometimes inconclusive. Even when a sample is obtained, pathologists may disagree on whether the cells are healthy or diseased, leaving patients and their families in limbo.The study found a way to detect and analyze rare blood-forming stem cells that occasionally escape the bone marrow and enter the bloodstream. These elusive cells, though few — often just one in a million — carry a wealth of diagnostic information.“As we age, our blood stem cells accumulate mutations,” explains Prof. Shlush. “These mutated cells eventually dominate the blood system, failing to produce healthy blood cells and laying the groundwork for conditions like myelodysplastic syndrome (MDS) and leukemia.”Traditionally, these defective cells are hidden within the bone marrow, undetectable by standard blood tests. Bone marrow biopsies, while effective, are painful, costly, and often inconclusive. But this new method captures and analyzes the rare migratory stem cells through a simple blood draw, combined with advanced single-cell genetic sequencing.How a Simple Blood Test Changes Cancer Diagnosis?The breakthrough came when Dr. Nili Furer, Nimrod Rappoport, and Oren Milman, collaborating with researchers in Israel and the U.S., discovered that rare blood stem cells occasionally escape the bone marrow and circulate in the bloodstream. These migrating cells, though extremely scarce—sometimes just a handful in a milliliter of blood—carry crucial diagnostic information.By applying advanced single-cell genetic sequencing, the researchers were able to isolate and analyze these rare cells, identifying early signs of MDS and assessing an individual’s risk of developing blood cancer. This approach allows for the detection of disease processes long before symptoms arise, offering a window of opportunity for early intervention.Focus on Myelodysplastic SyndromeThe study centers on myelodysplastic syndrome (MDS) — an age-related condition where stem cells fail to mature properly, leading to ineffective blood production and a heightened risk of progressing to acute myeloid leukemia (AML), a particularly aggressive form of cancer.Previously, diagnosing MDS required extracting marrow with a needle — an uncomfortable procedure that many patients dreaded. Now, thanks to this innovation, the same diagnosis can be made using peripheral blood samples. Dr. Nili Furer, along with collaborators Nimrod Rappoport and Oren Milman, played a critical role in demonstrating that these rare stem cells in blood are sufficient for detecting MDS and its progression risk.Why Men Age Faster — At Least in Their Blood?One of the study’s more striking revelations involves gender differences in blood aging. The researchers observed that stem cell aging occurs faster in men than in women, which may explain why blood cancers are more prevalent in males.“Men’s stem cells begin to exhibit cancer-prone mutations earlier than women’s,” notes Prof. Shlush. “This gender-based variance in blood aging is an eye-opener and may inform future prevention strategies.”The test not only identifies disease but also acts as a biological clock, providing new insights into how blood ages — revealing patterns that even bone marrow biopsies have failed to detect.Capturing and characterizing these rare cells required a blend of cutting-edge laboratory techniques and sophisticated data analysis. Each cell yielded tens of thousands of data points, and the team analyzed millions of cells from participants ranging in age from young adults to 95-year-olds. Prof. Tanay’s expertise in computational biology was instrumental in making sense of this vast dataset, enabling the team to distinguish healthy cells from those showing early signs of disease.Implications of The New Blood Test On TreatmentThe implications of this discovery are profound. Clinical trials based on the new blood test are already underway at multiple medical centers worldwide. The researchers believe that, in time, this test could be used not only for MDS and leukemia but also for a broad spectrum of blood-related disorders. By providing a non-invasive, highly sensitive diagnostic tool, the test has the potential to spare millions of patients from the ordeal of bone marrow biopsies each year.“As part of the aging process, stem cells—the ones capable of generating all blood cells—undergo genetic changes and mutations,” explains Prof. Shlush. “With time, these cells accumulate mutations and begin to dominate the blood system. They stop differentiating properly, produce only themselves, and suppress the production of healthy cells. Eventually, this can lead to deadly diseases like blood cancers.”The research itself is as resilient as its scientists. Just days before the study’s release, the labs of Profs. Shlush and Tanay at the Weizmann Institute were severely damaged in an Iranian missile attack. Despite the destruction, the team pushed forward, ensuring the findings reached the scientific community on time.The study reflects the combined efforts of a global team of physicians, biologists, and data scientists across Israel and the United States, proving that science endures even in the face of adversity.The prospect of replacing an invasive, expensive, and often ambiguous diagnostic procedure with a quick, precise, and painless blood test is a major leap forward. For millions worldwide, this means earlier detection, better prognosis, and more effective treatment strategies — all from a single vial of blood.

This New Blood Test Could Spot Leukemia Risk Without The Painful Bone Marrow Sampling

Quick Stories

India’s Drug Regulator Flags 186 Medicines For Failing Quality Test, Paracetamol And Diabetes Meds Included

Why Whooping Cough, Measles And Rubella Still Haunt U.S. Families, Here's What Vaccine Hesitancy Overlooks

Hepatitis A Outbreak In Europe: ECDC Confirms Over 2,000 Cases In Austria, Hungary, Czechia, Slovakia

Health Conditions A-Z

Rising Lower Back-Pain Risk See Improvement After These Many Minutes Of Walking

India’s Drug Regulator Flags 186 Medicines For Failing Quality Test, Paracetamol And Diabetes Meds Included

This New Blood Test Could Spot Leukemia Risk Without The Painful Bone Marrow Sampling